| NCT ID | NCT04157049 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Alpha-1 Foundation |
| Condition | Alpha 1-Antitrypsin Deficiency |
| Study Type | OBSERVATIONAL |
| Enrollment | 4,000 participants |
| Start Date | 2019-06-20 |
| Primary Completion | 2029-06-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 4,000 participants in total. It began in 2019-06-20 with a primary completion date of 2029-06-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The Alpha-1 Research Registry is a confidential database made up of individuals diagnosed with Alpha-1 Antitrypsin Deficiency (Alpha-1) and individuals identified as Alpha-1 carriers. The Registry was established to facilitate research initiatives and promote the development of improved treatments and a cure for Alpha-1.
Eligibility Criteria
Inclusion Criteria: * Patients diagnosed with Alpha-1 Antitrypsin Deficiency (PiZZ, PiZNull, PiSZ etc.) * Alpha-1 carriers (PiMZ, PiMS etc.) Exclusion Criteria: * Failure to provide informed consent * Normal healthy individuals (MM)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04157049 clinical trial?
This trial is open to participants of all sexes, studying Alpha 1-Antitrypsin Deficiency. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04157049 currently recruiting?
Yes, NCT04157049 is actively recruiting participants. Contact the research team at akeaveny@alpha1.org for enrollment information.
Where is the NCT04157049 trial being conducted?
This trial is being conducted at Coral Gables, United States.
Who is sponsoring the NCT04157049 clinical trial?
NCT04157049 is sponsored by Alpha-1 Foundation. The trial plans to enroll 4,000 participants.